RE:Company buyout price vs share price.Yes Canadafan you have "written" on this many times .. but many of your wrongs don't necessarily make you right.
For example"de-risking", involves removing many of the unknowns surrounding clincal development and demonstrates that a drug is effective. In other words "de-risking" is a "win-win-win" for patients, biotech (the acquirer) and investors (both for those in the acquired company as well as for those investors in the acquiring company). In otherwords 'de-risking' shows that the acquired company's product is effective and the acquisition is accretive. But in today's world of biotech acquisition, Big Pharma is more and more often acquiring early stage comany's that have not de-risked either their company's or their products ( I have posted many such examples of this on this message board). And having Canadafan bring in the topic of 'class-action law-suits" is just another RED HERRING. that has been a long-standing example of Canadafan's MO or perverse lack of current business development knowledge (as further seen in his advocacy of Andrew de G.).